| MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. |
globenewswire.com |
2025-05-12 12:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences to Participate in Citizens and RBC May Investor Conferences |
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21. |
globenewswire.com |
2025-04-22 12:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference |
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference. |
globenewswire.com |
2025-03-26 10:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights |
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025 Investigational New Drug submission anticipated in Q2 2025 for MBX 4291 in obesity $262.1 million in cash, cash equivalents and marketable securities as of December 31, 2024; expected to support operations into mid-2027 CARMEL, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress. |
globenewswire.com |
2025-03-17 10:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences Announces Additions to Leadership Team |
Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind. |
globenewswire.com |
2025-03-05 10:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism |
CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of enrollment in its Phase 2 Avail™ trial of MBX 2109 (canvuparatide), the Company's parathyroid hormone (PTH) peptide prodrug. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences to Participate in March Investor Conferences |
CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Monday, March 3, 2025Format: Podium Presentation and 1x1 meetingsTime: 10:30 a.m. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia |
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH) , which is expected to begin in 2H 2025 |
globenewswire.com |
2025-01-07 09:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia |
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH). |
globenewswire.com |
2024-11-18 10:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences to Participate in Upcoming November Investor Conferences |
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-10-28 10:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting |
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company's potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held in Toronto, ON, Canada September 27-30, 2024. |
globenewswire.com |
2024-09-30 12:00:00 |
Czytaj oryginał (ang.) |
| Last Week's 3 Biotech IPOs Prompt Huge Insider Buying |
24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares. |
247wallst.com |
2024-09-22 13:15:45 |
Czytaj oryginał (ang.) |
| MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares |
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses. |
globenewswire.com |
2024-09-16 20:05:00 |
Czytaj oryginał (ang.) |
| U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market |
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election. |
seekingalpha.com |
2024-09-14 09:00:00 |
Czytaj oryginał (ang.) |
| MBX Biosciences shares surge 44% in blockbuster Nasdaq debut |
Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, rose nearly 44% in their Nasdaq debut on Friday, underscoring investors' focus on weight-loss drugs. |
reuters.com |
2024-09-13 16:36:18 |
Czytaj oryginał (ang.) |
| MBX Biosciences raises $163.2 mln in US IPO |
MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering. |
reuters.com |
2024-09-12 23:20:42 |
Czytaj oryginał (ang.) |
| MBX Biosciences Announces Pricing of Initial Public Offering |
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $163.2 million. All of the shares are being offered by MBX Biosciences. In addition, MBX Biosciences has granted the underwriters a 30-day option to buy an additional 1,530,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. |
globenewswire.com |
2024-09-12 23:11:00 |
Czytaj oryginał (ang.) |